Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Lung Neoplasms 84Prostatic Neoplasms 73Leukemia, Myeloid, Acute 73Carcinoma, Non-Small-Cell Lung 61Neoplasm Metastasis 60Breast Neoplasms 56Multiple Myeloma 47Colorectal Neoplasms 47Pancreatic Neoplasms 43Carcinoma, Renal Cell 36Myelodysplastic Syndromes 35Melanoma 35Ovarian Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 30Triple Negative Breast Neoplasms 28Glioblastoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 25Lymphoma 23Squamous Cell Carcinoma of Head and Neck 22Burkitt Lymphoma 22Fallopian Tube Neoplasms 21Glioma 20Carcinoma, Hepatocellular 20Brain Neoplasms 18Mouth Neoplasms 17Lymphoma, Non-Hodgkin 17Leukemia, Biphenotypic, Acute 17Endometrial Neoplasms 17

Interventions

pembrolizumab 7lenvatinib 3apatinib 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Carboplatin 3gallium 68 PSMA-11 2Specimen Handling 2Protons 2Nivolumab 2Epirubicin 2Cisplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Trastuzumab 1Tablets 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Adenoid Cystic × Specimen Handling × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡